Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GALC CRISPR/Cas9 KO Plasmid (h): sc-401025
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GALC CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GALC genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GALC Antibody (2D1): sc-293200
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GALC CRISPR/Cas9 KO Plasmid (h) | sc-401025 | 20 µg | $397.00 |
Overview
GALC encodes galactocerebrosidase, a lysosomal hydrolase that catabolizes galactolipids such as galactosylceramide and psychosine, supporting sphingolipid turnover and myelin lipid homeostasis. By contributing to lysosome-dependent membrane lipid recycling, GALC links lysosomal function with broader pathways in sphingolipid metabolism, cellular stress responses, and neuroglial physiology. Altered GALC activity is associated with dysregulated psychosine handling and perturbed myelin-related lipid balance, making it relevant to studies of leukodystrophy mechanisms and lysosome-driven neurodegenerative processes. In human cells, GALC serves as a useful node for dissecting how lysosomal lipid catabolism shapes membrane composition, trafficking, and cell viability.
GALC CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GALC gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GALC together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GALC open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GALC protein expression.
This CRISPR knockout system enables efficient generation of GALC-deficient cell models for investigation of GALC signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GALC exon(s) critical for GALC function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GALC genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GALC CRISPR/Cas9 KO Plasmid (h) and GALC CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GALC locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GALC HDR Plasmid (h) and GALC HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GALC homology arms to support homology-directed repair at defined GALC target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.